research Two Incidental Sibling Diagnoses of Netherton Syndrome in Separate Visits: A Case Report
Doctors should consider Netherton syndrome in patients with chronic skin and hair issues to avoid misdiagnosis.
Search
for
Sort by
Research
750-780 / 1000+ results research Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
research Niacin deficiency increases the sensitivity of rats to the short and long term effects of ethylnitrosourea treatment.
Niacin deficiency makes rats more sensitive to cancer-causing chemicals.
research 186 Mechanistic insights into Ritlecitinib-mediated immunomodulation in Alopecia Areata
research β-Nicotinamide Mononucleotide Promotes Cell Proliferation and Hair Growth by Reducing Oxidative Stress
NMN could potentially treat hair loss by reducing oxidative stress and improving cell health.
research Fast clinical response with topical ruxolitinib in the management of non-segmental vitiligo detected by VISIA<sup>®</sup> analysis system
Topical ruxolitinib quickly improves non-segmental vitiligo.
research Combination of Netherton Syndrome and Hypopituitarism with Isolated Somatotropin Deficiency: Case Study
Treating Netherton syndrome with growth hormone and dupilumab improves growth safely.
research Smoothened antagonists for hair inhibition
Two new compounds were found to effectively reduce hair growth in mice.
research LB822 Nutraceuticals known to promote hair growth do not interfere with the inhibitory action of tamoxifen in breast cancer cells
Hair growth supplements do not reduce the effectiveness of the breast cancer treatment tamoxifen.
research 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.
research 27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial
Baricitinib was effective in treating both early and late onset alopecia areata.
research Sorafenib-induced eruption resembling pityriasis rubra pilaris
A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.
research Naringin Promotes Hair Regeneration via Wnt/β-catenin Pathway: A Dose-Dependent Study in C57BL/6J Mice
research PNU 157706, a novel dual type I and II5α-reductase inhibitor
PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
research Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation
Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
research Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research 1103 Derinat extends hair cycle at anagen phase by decreasing the level of TRPCs-mediated intracellular ROS accumulation in skin
Derinat helps extend hair growth by reducing harmful molecules in skin cells.
research Synthesis and Structure–Activity Relationships of the First Ferrocenyl-Aryl-Hydantoin Derivatives of the Nonsteroidal Antiandrogen Nilutamide
Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
research LB1009 Baicalin, a component of the herbal medicine Baikal skullcap, inhibits epidermal necroptosis in SJS/TEN
Baicalin may help treat severe drug-induced skin reactions.
research 0480 Upadacitinib monotherapy for treatment of pyoderma gangrenosum: A case series
Upadacitinib effectively treats pyoderma gangrenosum.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib
Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
research BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
research Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
research Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
research Discovery and Optimization of Novel Pyridines as Highly Potent and Selective Glycogen Synthase Kinase 3 Inhibitors
New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.
research Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
Low-dose tofacitinib is effective and cheaper for severe alopecia areata.